BRCA1 and ovarian carcinoma: Knocking out PPARGC1A in breast or ovarian cancer mouse models with mutated BRCA1/2 [50,51,52] will also help to investigate the effect of PPARGC1A in increasing cancer risk in the context of BRCA1/2 mutations and to reveal the underlying biological mechanism.